Open AccessPhase I study on pegylated liposomal doxorubicin in combination with docetaxel for patients with platinum-resistant or partially platinum-sensitive epithelial ovarian cancer: The Kansai Clinical Oncology Group study
Author(s) -
Kensuke Hori,
Kimihiko Ito,
Kentaro Kuritani,
Shiho Kuji,
Naoto Furukawa,
Hiroshi Taniguchi,
Atsushi Arakawa
Publication year - 2019
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_742_16
Subject(s) - docetaxel , medicine , neutropenia , ovarian cancer , adverse effect , chemotherapy , regimen , phases of clinical research , oncology , gastroenterology , combination therapy , cancer
In platinum-resistant ovarian cancer, single-agent chemotherapy is recommended for the reduction of adverse events. However, in clinical practice, some patients can tolerate drug-specific adverse events.